Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
ZNTLthis companyZentalis Pharmaceuticals, Inc.	$1.76	-0.71×	0.45×	0×	-0.7×	-106.2%	0.0%	0.0%	0.0%	-63.4%	-59.6%	-129.1%	0.18×	-0.02×	0×	6.93×	0.0%	2	-9.02	1	C-
ALXOALX Oncology Holdings Inc.	$1.22	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
ARTVArtiva Biotherapeutics, Inc.	$4.21	-1.25×	0.95×	0×	-1.1×	-84.3%	0.0%	0.0%	0.0%	-76.3%	-74.9%	-75.7%	0.1×	0.19×	0×	8.61×	0.0%	1	4.66	2	C+
DTILPrecision BioSciences, Inc.	$10.73	-1.17×	0.58×	1.56×	0.68×	-257.3%	100.0%	-152.2%	-133.4%	-49.6%	-35.5%	-123.6%	0.31×	1.93×	-36.67×	13.32×	0.0%	3	-4.84	1	C-
IMMXImmix Biopharma, Inc.	$8.63	-5.88×	1.84×	0×	-2.69×	-63.4%	0.0%	0.0%	0.0%	-31.4%	-31.6%	-14.3%	0.01×	3.14×	0×	10.01×	0.0%	2	35.26	2	C+
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
Peer median	—	-1.25×	1.83×	0×	-1.1×	-90.6%	0.0%	0.0%	0.0%	-76.3%	-35.5%	-81.6%	0.2×	0.19×	-8.56×	8.61×	0.0%	2	-2.66	2	—